Novo Nordisk faces off in court with South African weight-loss drug compounder

Novo Nordisk is going to court in South Africa on Wednesday to try to stop the sale of unapproved semaglutide copies, protecting the active ingredient used in Wegovy and Ozempic. The case underscores ongoing legal and regulatory pressure around copycat versions of its blockbuster obesity and diabetes drugs. The news is mildly negative for Novo because it highlights enforcement risk, though the immediate market impact should be limited.

Analysis

Novo Nordisk is going to court in South Africa on Wednesday to try to stop the sale of unapproved semaglutide copies, protecting the active ingredient used in Wegovy and Ozempic. The case underscores ongoing legal and regulatory pressure around copycat versions of its blockbuster obesity and diabetes drugs. The news is mildly negative for Novo because it highlights enforcement risk, though the immediate market impact should be limited.